2. Search Result
Search Result
Results for "

Adenosine+diphosphate

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Biochemical Assay Reagents

7

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010918
    Adenosine 5'-diphosphate
    5+ Cited Publications

    Adenosine diphosphate; ADP

    		 Endogenous Metabolite Others
    Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate
  • HY-P2764
    Apyrase
    3 Publications Verification

    		 NTPDase Inflammation/Immunology
    Apyrase is an Nucleoside triphosphate diphosphohydrolase (NTPDase). Apyrase can hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP). Apyrase can inhibit Stx2 toxin release of enterohemorrhagic Escherichia coli (EHEC) infection and protect the intestinal barrier function. Apyrase can be used for the research of infection and inflammation, such as hemorrhagic colitis .
    Apyrase
  • HY-19638A
    Cangrelor tetrasodium
    4 Publications Verification

    AR-C69931MX tetrasodium

    		 P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium
  • HY-D0199
    Adenosine 5'-diphosphate disodium
    5+ Cited Publications

    Adenosine diphosphate disodium; ADP disodium

    		 Endogenous Metabolite Cardiovascular Disease
    Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .
    Adenosine 5'-diphosphate disodium
  • HY-150508
    MK-0159
    1 Publications Verification

    		 CD38 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
    MK-0159
  • HY-108708
    GeA-69

    		PARP Cancer
    GeA-69 is a selective, allosteric inhibitor of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) targeting macrodomain 2 (MD2), with a Kd value of 2.1 μM. GeA-69 involves in DNA damage repair mechanisms and prevents recruitment of PARP14 MD2 to sites of laser-induced DNA damage .
    GeA-69
  • HY-107867
    (±)-Clopidogrel bisulfate

    		P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .
    (±)-Clopidogrel bisulfate
  • HY-W010918S2
    Adenosine 5'-diphosphate-15N5 dilithium

    Adenosine diphosphate-15N5 dilithium; ADP-15N5 dilithium

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease
    Adenosine 5'-diphosphate- 15N5 (Adenosine diphosphate- 15N5 dilithium) dilithium is 15N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-15N5 dilithium
  • HY-171213
    NB-3

    		Toll-like Receptor (TLR) Neurological Disease
    NB-3 is a nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 inhibitor. NB-3 intercepts NAD hydrolysis and undergoes covalent conjugation with the reaction product adenosine diphosphate ribose (ADPR). The resulting small-molecule ADPR adducts are highly potent and confer compelling neuroprotection in neurological injury .
    NB-3
  • HY-19638
    Cangrelor

    AR-C69931MX

    		 P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
    Cangrelor
  • HY-W010918S3
    Adenosine 5'-diphosphate-13C5

    Adenosine diphosphate-13C5; ADP-13C5

    		 Isotope-Labeled Compounds Endogenous Metabolite Others
    Adenosine 5'-diphosphate- 13C5 (Adenosine diphosphate- 13C5) is the 13C-labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-13C5
  • HY-W010918R
    Adenosine 5'-diphosphate (Standard)

    Adenosine diphosphate (Standard); ADP (Standard)

    		 Reference Standards Endogenous Metabolite Others
    Adenosine 5'-diphosphate (Standard) is the analytical standard of Adenosine 5'-diphosphate. This product is intended for research and analytical applications. Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors. In Vitro: Adenosine 5'-diphosphate consists of the pyrophosphate group, the pentose sugar ribose, and the nucleobase adenine. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. ADP is converted back to ATP by ATP synthases. ATP is an important energy transfer molecule in cells. Adenosine 5'-diphosphate is utilized in a wide number of cellular processes, including respiration, biosynthetic reactions, motility, and cell division.
    Adenosine 5'-diphosphate (Standard)
  • HY-D0199R
    Adenosine 5'-diphosphate disodium (Standard)

    Adenosine diphosphate disodium (Standard); ADP disodium (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .
    Adenosine 5'-diphosphate disodium (Standard)
  • HY-123669
    R-138727

    		P2Y Receptor Drug Metabolite Cardiovascular Disease
    R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
    R-138727
  • HY-117804
    8-Br-cADPR

    8-Bromo-Cyclic ADP-Ribose

    		 TRP Channel Neurological Disease Metabolic Disease
    8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose), a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR reduces renal damage and the expression of caspase-3 and TRPM2 .
    8-Br-cADPR
  • HY-175081
    8-Br-cADPR sodium salt

    8-Bromo-Cyclic ADP-Ribose sodium salt

    		 TRP Channel Metabolic Disease
    8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose) sodium salt, a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR sodium salt reduces renal damage and the expression of caspase-3 and TRPM2 .
    8-Br-cADPR sodium salt
  • HY-10419A
    AH23848 hemicalcium salt
    1 Publications Verification

    		 Prostaglandin Receptor Cardiovascular Disease
    AH23848 hemicalcium salt is an orally active, selective competitive blocker of the thromboxane A2 receptor, with an IC50 value of 50 nM. AH23848 hemicalcium salt shows no activity against other prostaglandin, serotonin (5-HT) or adenosine diphosphate (ADP) receptors. AH23848 hemicalcium salt can be used in the research of occlusive vascular diseases .
    AH23848 hemicalcium salt
  • HY-19638AR
    Cangrelor tetrasodium (Standard)

    AR-C69931MX tetrasodium (Standard)

    		 P2Y Receptor Reference Standards Cardiovascular Disease Inflammation/Immunology
    Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium (Standard)
  • HY-N13135
    Kadsutherin G

    		Others Cardiovascular Disease
    Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .
    Kadsutherin G
  • HY-160993
    Ciprostene

    9β-Methylcarbacyclin

    		 Prostaglandin Receptor Cardiovascular Disease
    Ciprostene is analog of prostacyclin (PGI2). Ciprostene inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene can be used for research of peripheral vascular disease .
    Ciprostene
  • HY-122499
    Ciprostene calcium

    		Prostaglandin Receptor Cardiovascular Disease
    Ciprostene calcium is a prostacyclin analogue.Ciprostene calcium inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene calcium can be used for research of peripheral vascular disease .
    Ciprostene calcium
  • HY-N13134
    Kadsutherin F

    		Others Cardiovascular Disease
    Kadsutherin F (compound 2) is a lignin that can be isolated from Kadsura. Kadsutherin F has an inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation with an inhibition rate of 49.47% .
    Kadsutherin F
  • HY-N4266
    Vinaginsenoside R8

    		Others Cardiovascular Disease
    Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC50=25.18 μM) .
    Vinaginsenoside R8
  • HY-110124
    ML202

    		Pyruvate Kinase Cancer
    ML202 is a highly specific allosteric activator of human pyruvate kinase M2 (hPK-M2), which can affect the cooperativity of phosphoenolpyruvate (PEP) binding, while adenosine diphosphate (ADP) binding almost no effect .
    ML202
  • HY-163785
    1"-α-Azido-RDPr

    		SARS-CoV Infection
    1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
    1
  • HY-107867S1
    (Rac)-Clopidogrel hydrogen-d9 sulfate

    		Isotope-Labeled Compounds P2Y Receptor Inflammation/Immunology
    (Rac)-Clopidogrel hydrogen-d9 sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .
    (Rac)-Clopidogrel hydrogen-d9 sulfate
  • HY-107867S2
    Clopidogrel-13C,d3 sulfate

    		Isotope-Labeled Compounds P2Y Receptor Cardiovascular Disease
    Clopidogrel- 13C,d3 sulfate is the deuterium and 13C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .
    Clopidogrel-13C,d3 sulfate
  • HY-106394
    TP-9201

    		P-glycoprotein Cardiovascular Disease
    TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC50 = 1-3 μM), while showing lower activity in rabbits (IC50 = 45 μM) and rats (IC50 = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis .
    TP-9201
  • HY-114986
    6-Keto-PGE1
    1 Publications Verification

    6-keto-Prostaglandin E1

    		 β-glucuronidase Cardiovascular Disease
    6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock .
    6-Keto-PGE1
  • HY-182249
    Aristeromycin 5′-diphosphate

    ArDP

    		 Drug Derivative Others
    Aristeromycin (ArDP) 5′-diphosphate is a carbocyclic nucleotide analog of adenosine diphosphate (ADP). Aristeromycin 5′-diphosphate acts as a key intermediate in the synthesis of bioactive compounds .
    Aristeromycin 5′-diphosphate
  • HY-182625
    GS-1160-180

    		Platelet-activating Factor Receptor (PAFR) Others Inflammation/Immunology
    GS-1160-180 is a PAF receptor antagonist. GS-1160-180 competes with PAF for receptor binding, with no activity against collagen or adenosine diphosphate-induced platelet aggregation. GS-1160-180 can be used for research on asthma, anaphylactic shock, gastric ulceration, and transplant rejection .
    GS-1160-180
  • HY-W676872
    Dihydroflavokawin B

    		COX Parasite Infection Inflammation/Immunology
    Dihydroflavokawin B is a selective COX-1 inhibitor with an IC50 of 1.22 μM. Dihydroflavokawin B weakly inhibits COX-2 and 5-LOX. Dihydroflavokawin B inhibits promastigote forms of Leishmania panamensis and Leishmania braziliensis. Dihydroflavokawin B inhibits rabbit platelet aggregation induced by Arachidonic acid, platelet activating factor, and adenosine diphosphate. Dihydroflavokawin B exhibits in vitro anti-inflammatory activity. Dihydroflavokawin B can be used for the research of leishmaniasis .
    Dihydroflavokawin B
  • HY-15283AS1
    (±)-Clopidogrel-d4

    (±)-Clopidogrelum-d4

    		 Isotope-Labeled Compounds P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    (±)-Clopidogrel-d4 ((±)-Clopidogrelum-d4) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .
    (±)-Clopidogrel-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: